点击图片查看原图
Hep G2.2.15 人肝癌（HBV)
人结肠癌氟尿嘧啶耐药株 HCT-8/FU
通过南京市浦口区市场监督管理局认证 
| 数量： | 大量 |
| 生长状态： | 贴壁生长 |
| 运输方式： | 冻存运输 |
| 细胞形态： | 上皮样 |
| 是否是肿瘤细胞： | 0 |
| 物种来源： | 小鼠 |
| 器官来源： | 乳腺 |
| ATCC Number： | CRL-2539™ |
| 相关疾病： | 肿瘤 |
| 品系： | BALB/cfC3H |
| Designations: | 4T1 | ||
| Depositors: | BA Pulaski | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Mus musculus deposited as mouse | ||
| Morphology: | epithelial | ||
| Source: | Organ: mammary gland Strain: BALB/cfC3H Disease: tumor | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Applications: | 4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics. Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models. When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ. | ||
| Tumorigenic: | Yes | ||
| Comments: | 4T1 is a 6-thioguanine resistant cell line selected from the 410.4 tumor without mutagen treatment. When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ. The primary tumor does not have to be removed to induce metastatic growth. The tumor growth and metastatic spread of 4T1 cells in BALB/c mice very closely mimic human breast cancer. This tumor is an animal model for stage IV human breast cancer. 4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics. Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models. There is no need to count nodules or weight target organs. | ||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% | ||
| Subculturing: | Protocol: NOTE: the cells should not be allowed to become confluent, subculture at 80% of confluence. Remove medium, and rinse with 0.25% trypsin-0.53mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37.0°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:8 is recommended Medium Renewal: Every 2 to 3 days | ||
| Preservation: | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 | ||
| References: | 49687: Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864 49688: Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252 49689: Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145 49690: Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948 | ||
![SHG-44 [SHG44]](images/413/A1464237784558e4nfk8m6yi.png)
